Edition:
United States

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

25.90USD
20 Jul 2018
Change (% chg)

$-0.39 (-1.48%)
Prev Close
$26.29
Open
$26.27
Day's High
$26.37
Day's Low
$25.55
Volume
31,880
Avg. Vol
75,415
52-wk High
$38.35
52-wk Low
$21.27

Select another date:

Thu, May 17 2018

BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End

* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

Select another date: